Skip to main content

Table 2 Summary of subgroup analyses

From: Clinical relevance between sodium-glucose co-transporter 2 inhibitors and lipid profiles in Asian patients with type 2 diabetes mellitus: a systematic review with a meta-analysis of randomized controlled trials

 OutcomeTrial, nSGLT2i, nPlacebo, nMean difference [95%CI]Heterogeneity
(%)
Test for the overall effect
(p value)
Only Japanese patientsHbA1c (%)131998866− 0.83 [− 1.01, − 0.65]90< 0.00001
TG (mg/dL)132127848−14.39 [−20.80, −7.98]0< 0.0001
HDL-C (mg/dL)1219457943.58 [2.90, 4.25]0< 0.00001
LDL-C (mg/dL)1219457942.59 [0.72, 4.46]00.007
LDL-C/HDL-C ratio2402125−0.04 [−0.12, 0.04]00.33
Only patients treated with SGLT2i as monotherapyHbA1c (%)81596647−0.84 [− 0.97, − 0.70]77< 0.00001
TG (mg/dL)71464497−17.96 [−27.03, −8.88]00.0001
HDL-C (mg/dL)612824433.89 [3.01, 4.76]0< 0.00001
LDL-C (mg/dL)612824434.29 [1.81, 6.76]00.0007
LDL-C/HDL-C ratio130775−0.04 [−0.13, 0.05]NA0.37
  1. SGLT2i the sodium-glucose co-transporter 2 inhibitor, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglycerides, CI confidence interval, NA not applicable